Xuan Yin Ning Plus Bevacizumab for Malignant Pleural Effusion (XYN-Bev MPE)
A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Study of Xuan Yin Ning Formula Combined With Intrapleural Injection of Bevacizumab for the Treatment of Malignant Pleural Effusion.
The goal of this clinical trial is to determine whether the Xuanyin Ning Formula combined with intrapleural injection of bevacizumab via chest tube drainage is effective in treating malignant pleural effusion. It will also evaluate the safety of this combination therapy. The main questions it aims to answer include:
Does the Xuanyin Ning Formula combined with intrapleural injection of bevacizumab via chest tube drainage improve the objective response rate (ORR) of pleural effusion in patients with malignant pleural effusion? Does this combination therapy affect the duration of response (DoR), progression-free survival (PFS), overall survival (OS), degree of dyspnea, quality of life, and Traditional Chinese Medicine (TCM) pattern/syndrome evaluation in patients with malignant pleural effusion?
Participants will:
Receive intrapleural injection of bevacizumab via chest tube drainage, and take either Xuanyin Ning Formula or placebo granules daily for 8 weeks.
Undergo ultrasound assessment of pleural effusion at 2, 4, 8, and 12 weeks after the first intrapleural injection during closed chest drainage, followed by ultrasound assessments every 3 months (±7 days) until pleural effusion progression.
연구 개요
상태
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 연락처
- 이름: Ming Zhang
- 전화번호: 18017320233
- 이메일: gason2000@126.com
연구 장소
-
-
Hebei
-
Wuhan, Hebei, 중국, 430022
- Wuhan First Hospital
-
연락하다:
- Zuowei Hu
- 전화번호: 13871029959
- 이메일: 827823053@qq.com
-
-
Henan
-
Xinxiang, Henan, 중국, 453100
- The First Affiliated Hospital of Xinxiang Medical University
-
연락하다:
- Xiaohong Kang
- 전화번호: 19838276658
- 이메일: 394161891@qq.com
-
-
Shandong
-
Weifang, Shandong, 중국, 261041
- Weifang Traditional Chinese Medicine Hospital 或 Weifang Traditional Chinese Hospital
-
연락하다:
- Chaoguang Yan
- 전화번호: 19953614610
- 이메일: 19953614610@126.com
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, 중국, 200030
- Shanghai Chest Hospital
-
연락하다:
- Ming Zhang
- 전화번호: 18017320233
- 이메일: gason2000@126.com
-
Shanghai, Shanghai Municipality, 중국, 200437
- Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine
-
연락하다:
- Yabin Gong
- 전화번호: 18918923873
- 이메일: gongyabin@hotmail.com
-
Shanghai, Shanghai Municipality, 중국, 200032
- Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
-
연락하다:
- Zhongqi Wang
- 전화번호: 18917763093
- 이메일: aledx@sina.com
-
Shanghai, Shanghai Municipality, 중국, 202157
- Shanghai Tenth People's Hospital Chongming Branch
-
연락하다:
- Yeyun Lu
- 전화번호: 18916582319
- 이메일: 307997868@qq.com
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
설명
Inclusion Criteria:
- Patients with advanced non-squamous non-small cell lung cancer who have failed at least first-line systemic therapy;
- Presence of unilateral pleural effusion confirmed as malignant by pathology or cytology, with at least moderate volume requiring drainage (moderate pleural effusion defined as: supine ultrasound examination showing pleural effusion ≥3 cm, or sitting ultrasound examination showing pleural effusion ≥4 cm,accompanied by clinical symptoms such as chest tightness and dyspnea);
- Age 18-75 years;
- ECOG performance status 0-2;
- Traditional Chinese Medicine (TCM) syndrome differentiation classified as Xuanyin (suspension fluid) with fluid retention in the chest and hypochondrium;
- Expected survival of at least 3 months;
- Voluntarily signed informed consent before treatment;
- No contraindications to chest tube placement for drainage;
Adequate major organ function, including:
Complete blood count:
White blood cell count ≥ 4.0×10⁹/L Absolute neutrophil count ≥ 1.5×10⁹/L Platelet count ≥ 100×10⁹/L Hemoglobin ≥ 90 g/L
Blood biochemistry:
Total bilirubin ≤ 1.5×ULN ALT ≤ 2.5×ULN, AST ≤ 2.5×ULN Serum creatinine ≤ 1.5×ULN, or creatinine clearance ≥ 50 mL/min (Cockcroft-Gault formula)
Coagulation function:
International normalized ratio (INR) ≤ 1.5×ULN Activated partial thromboplastin time (APTT) ≤ 1.5×ULN
- Blood glucose: within normal range, or diabetic patients under treatment with stable blood glucose control;
- Female subjects of childbearing potential must have a negative serum pregnancy test within 72 hours before starting study drug administration, and must use effective contraception (e.g., intrauterine device, contraceptive pills, or condoms) during the study period and for at least 3 months after the last dose. -Male subjects with a partner of childbearing potential must use effective contraception during the study period and for 3 months after the last dose;
- Good subject compliance, able to follow up for efficacy and adverse events/reactions as required by the protocol.
Exclusion Criteria:
- The location of pleural effusion is unsuitable for drainage, or the patient would not benefit from intrapleural drug administration (e.g., severe loculation/septation);
- Other contraindications to indwelling chest tube placement;
- Pleural effusion with active infection;
- Prior history of ipsilateral chest tube drainage and intrapleural anti-tumor drug therapy or pleurodesis;
- Prior history of empyema or chylothorax;
- Participation in another clinical trial within 4 weeks before signing informed consent;
- Known allergy to any component of the study drugs;
- Severe bleeding tendency or active bleeding;
- Uncontrolled severe hypertension;
- Recent (within 3 months) thromboembolic events, such as deep vein thrombosis, pulmonary embolism, cerebral infarction, etc.;
- Prior severe adverse reactions to intravenous bevacizumab, such as severe proteinuria, gastrointestinal perforation, hypertensive crisis, etc.;
- Severe cardiac, hepatic, or renal insufficiency;
- Pregnant or breastfeeding women;
- Subjects with other active infectious diseases in the acute phase;
- Any other factors that, in the investigator's judgment, may lead to premature termination of the study, such as other serious diseases (including psychiatric disorders) requiring concomitant treatment, alcoholism, drug abuse, family or social factors that may affect the subject's safety or compliance.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 더블
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: 실험군
|
After chest tube drainage, bevacizumab 300 mg per dose, dissolved in 50 ml of normal saline, is injected intrapleurally.
The injection may be repeated after 2 weeks depending on the control of pleural effusion.
Xuanyin Ning is taken as 2 sachets per day, one sachet dissolved in water and taken orally in the morning and one in the evening.
Each treatment cycle is 4 weeks, and at least 2 cycles are required.
|
|
위약 비교기: 대조군
|
After chest tube drainage, bevacizumab 300 mg per dose, dissolved in 50 ml of normal saline, is injected intrapleurally.
The injection may be repeated after 2 weeks depending on the control of pleural effusion.
Placebo granules are taken as 2 sachets per day, one sachet dissolved in water and taken orally in the morning and one in the evening.
Each treatment cycle is 4 weeks, and at least 2 cycles are required.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
Objective Response Rate of pleural effusion (ORR)
기간: Before treatment and at 4 weeks, 8 weeks, and 12 weeks after treatment
|
Before treatment and at 4 weeks, 8 weeks, and 12 weeks after treatment
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Duration of Response (DoR)
기간: At 2, 4, 8, and 12 weeks after treatment
|
At 2, 4, 8, and 12 weeks after treatment
|
|
|
Progression-Free Survival (PFS)
기간: From date of treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
|
From date of treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
|
|
|
Overall Survival (OS)
기간: From date of treatment until the date of death from any cause, assessed up to 100 months
|
From date of treatment until the date of death from any cause, assessed up to 100 months
|
|
|
Degree of dyspnea
기간: At 2, 4, 8, and 12 weeks after treatment
|
At 2, 4, 8, and 12 weeks after treatment
|
|
|
ECOG score
기간: At 2, 4, 8, and 12 weeks after treatment
|
The ECOG score is a widely used clinical tool for quantifying a cancer patient's general well-being and functional capacity in daily life.
It is primarily employed in oncology trials, treatment planning, and prognosis assessment.
The scale ranges from 0 to 5, with higher numbers indicating greater disability
|
At 2, 4, 8, and 12 weeks after treatment
|
|
Traditional Chinese Medicine (TCM) syndrome evaluation
기간: At 2, 4, 8, and 12 weeks after treatment
|
Quantification: The scale standardizes the evaluation of clinical symptoms, signs, and tongue/pulse findings, which are traditionally assessed through the four examinations (inspection, hearing/smelling, inquiry, and palpation). Objectivity: It aims to improve the objectivity and standardization of TCM diagnosis and treatment evaluation. Efficacy Evaluation: It is frequently used to calculate a "total effective rate" based on the reduction in syndrome scores after treatment. Scoring: Symptoms are typically graded on a scale (e.g., 0 for normal, 2 for mild, 4 for moderate, 6 for severe), and the total score reflects the overall severity of the syndrome |
At 2, 4, 8, and 12 weeks after treatment
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .